Advanced Oncotherapy (LSE: AVO)
After six to seven years and over £130m of investment in intense technical development of the next generation of proton beam therapy (PBT) machines, today AVO took a significant commercial step forward. It announced that AVO have signed an LOI (Letter of Intent) with Saba Partners to purchase a three-treatment room LIGHT system for around £75.5m.
The system is to be installed at Glion in Switzerland which has been acquired by Saba Partners who are building a medical centre of excellence there. This is subject to a CE mark, which s...
